Icatibant acetate is a medication used for the treatment of hereditary angioedema (HAE), a rare genetic condition characterized by sudden and severe swelling of the skin, mucous membranes, and other body tissues. It is a selective bradykinin B2 receptor antagonist that works by blocking the effects of bradykinin, a key mediator of the swelling associated with HAE. Icatibant acetate is administered via subcutaneous injection and is designed to rapidly relieve symptoms of acute HAE attacks.